Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992054 | 0.91 | P2RX7 (0.46) | P2RX7P2RX3KMT2AALDH1A1ALOX12 | |
| SCHEMBL14272313 | 0.90 | TSHR (0.48) | P2RX7EPHX2SIGMAR1KMT2AALDH1A1 | |
| SCHEMBL13532485 | 0.89 | SIGMAR1 (0.41) | P2RX7SIGMAR1KMT2AALDH1A1MEN1 | |
| SCHEMBL4988062 | 0.88 | ALDH1A1 (0.42) | P2RX7KMT2AALDH1A1ALOX12MEN1 | |
| SCHEMBL4988064 | 0.88 | ALDH1A1 (0.47) | P2RX7KMT2AALDH1A1ALOX12MEN1 | |
| SCHEMBL4984961 | 0.88 | P2RX7 (0.49) | P2RX7EPHX2P2RX3KMT2AALDH1A1 | |
| SCHEMBL4990757 | 0.88 | P2RX7 (0.47) | P2RX7EPHX2P2RX3 | |
| SCHEMBL4989509 | 0.87 | P2RX7 (0.47) | P2RX7P2RX3KMT2AALDH1A1ALOX12 | |
| SCHEMBL13533001 | 0.83 | SIGMAR1 (0.39) | SIGMAR1KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL4987092 | 0.83 | TSHR (0.42) | P2RX7EPHX2KMT2AALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| EP-1860942-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006102610-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885EPHX2 569/4885P2RX3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.